Profile data is unavailable for this security.
About the company
NGL Fine-Chem Limited is an India-based company, which is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health. The Company caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen and others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets. It has manufacturing plants located around Mumbai.
- Revenue in INR (TTM)3.72bn
- Net income in INR413.64m
- Incorporated1981
- Employees390.00
- LocationNgl Fine Chem Ltd301, E Square,, Subhash Road,, Vile ParlMUMBAI 400057IndiaIND
- Phone+91 2 240842222
- Fax+91 2 240539900
- Websitehttps://www.nglfinechem.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Albert David Ltd | 3.65bn | 685.47m | 7.33bn | 1.50k | 10.70 | 1.77 | 9.71 | 2.01 | 120.12 | 120.12 | 639.84 | 724.06 | 0.7377 | 2.83 | 10.89 | 2,439,081.00 | 13.85 | 10.00 | 17.15 | 13.15 | 66.12 | 59.85 | 18.77 | 11.87 | 3.65 | 53.46 | 0.0085 | 12.89 | 6.12 | 2.72 | 108.49 | 33.59 | 40.87 | 13.90 |
| Wanbury Ltd | 5.77bn | 529.62m | 7.36bn | 1.49k | 14.27 | 18.99 | 11.12 | 1.27 | 15.73 | 15.73 | 173.33 | 11.83 | 1.55 | 7.95 | 6.17 | 3,871,231.00 | 14.26 | 11.63 | 39.18 | -- | 49.84 | 42.46 | 9.18 | 7.62 | 0.6908 | 1.71 | 0.8235 | -- | 15.21 | 8.02 | 638.26 | -- | 29.87 | -- |
| Nectar Lifesciences Ltd | 16.79bn | 107.27m | 7.84bn | 1.69k | 73.39 | 0.7278 | 10.92 | 0.4671 | 0.4766 | 0.4766 | 73.70 | 48.06 | 0.7764 | 1.67 | 4.94 | 9,960,952.00 | 0.496 | -0.2956 | 0.8778 | -0.541 | 30.41 | 16.49 | 0.6388 | -0.4053 | 0.5576 | 1.25 | 0.3686 | -- | 10.53 | -9.56 | 120.66 | -36.29 | -5.06 | -- |
| Kopran Ltd | 6.36bn | 528.93m | 10.03bn | 358.00 | 15.68 | 2.02 | 14.86 | 1.58 | 13.26 | 13.26 | 150.57 | 103.15 | 0.8922 | 2.76 | 3.64 | 17,765,300.00 | 7.42 | 8.47 | 10.49 | 12.23 | 35.38 | 32.93 | 8.32 | 8.89 | 1.27 | 29.83 | 0.1997 | 25.41 | 11.54 | 11.42 | 87.11 | 16.23 | 12.53 | -- |
| Ngl Fine Chem Ltd | 3.72bn | 413.64m | 11.05bn | 390.00 | 26.72 | 3.94 | 29.05 | 2.97 | 66.95 | 66.95 | 601.51 | 453.70 | 1.03 | 4.37 | 5.12 | 9,529,503.00 | 11.51 | 15.06 | 14.90 | 19.58 | 51.59 | 43.53 | 11.13 | 13.15 | 2.17 | 25.70 | 0.1594 | 3.06 | 21.79 | 17.20 | 101.58 | 15.47 | 14.49 | 0.00 |
| Bajaj Healthcare Ltd | 5.08bn | -101.06m | 12.42bn | 944.00 | -- | 2.78 | 68.66 | 2.44 | -3.70 | -5.69 | 183.39 | 141.16 | 0.6186 | 1.54 | 2.33 | 5,379,316.00 | -1.23 | 7.67 | -2.35 | 14.11 | 47.51 | 33.26 | -1.99 | 7.99 | 1.21 | 1.95 | 0.3158 | 4.90 | -26.69 | 5.04 | -122.55 | -- | 15.08 | -- |
| Lincoln Pharmaceuticals Ltd | 5.97bn | 966.39m | 12.49bn | 1.70k | 12.92 | 1.95 | 11.50 | 2.09 | 48.25 | 48.25 | 298.31 | 319.16 | 0.828 | 3.77 | 3.40 | 3,514,339.00 | 13.39 | 13.95 | 15.85 | 16.54 | 52.60 | 50.65 | 16.18 | 14.71 | 3.64 | 60.48 | 0.0021 | 3.44 | 13.76 | 9.66 | 27.99 | 13.88 | 21.54 | 3.71 |
| Bliss GVS Pharma Ltd | 8.00bn | 634.20m | 12.71bn | 831.00 | 20.30 | 1.26 | 12.76 | 1.59 | 5.94 | 5.94 | 75.55 | 96.05 | 0.6454 | 3.10 | 1.98 | 9,628,987.00 | 5.80 | 6.46 | 7.04 | 8.22 | 50.26 | 43.91 | 8.99 | 9.92 | 3.74 | -- | 0.0825 | 7.92 | 2.48 | -3.03 | 6.49 | -9.42 | -8.33 | -12.94 |
| Remus Pharmaceuticals Ltd | 2.12bn | 215.37m | 13.88bn | 48.00 | 63.11 | 15.99 | 51.67 | 6.53 | 37.34 | 37.34 | 374.91 | 147.42 | 1.46 | 7.61 | 3.56 | 44,270,750.00 | 17.80 | -- | 44.48 | -- | 22.67 | -- | 12.22 | -- | 1.12 | 55.56 | 0.0997 | -- | 371.94 | -- | 153.29 | -- | -- | -- |
| Zota Health Care Ltd | 1.98bn | -242.34m | 14.72bn | 445.00 | -- | -- | 3,152.02 | 7.43 | -9.27 | -9.27 | 76.32 | -- | -- | -- | -- | 4,452,605.00 | -- | -1.38 | -- | -1.85 | 49.86 | 35.95 | -12.23 | -1.33 | -- | -2.87 | -- | -- | 28.96 | 16.08 | -148.54 | -- | 39.85 | 0.00 |
| Jagsonpal Pharmaceuticals Ltd | 2.27bn | 243.00m | 15.29bn | 1.03k | 64.24 | 7.75 | 53.59 | 6.74 | 8.98 | 8.98 | 83.78 | 74.42 | 0.9703 | 5.13 | 9.92 | 2,213,181.00 | 10.39 | 10.95 | 12.40 | 13.29 | 58.16 | 58.13 | 10.71 | 9.21 | 2.60 | 32.84 | 0.0474 | 43.81 | -11.83 | 4.58 | -15.94 | 25.50 | -35.69 | 82.06 |
| Holder | Shares | % Held |
|---|---|---|
| Motilal Oswal Asset Management Co. Ltd.as of 31 Oct 2024 | 37.00 | 0.00% |
| Bandhan AMC Ltd.as of 31 Oct 2024 | 23.00 | 0.00% |
